US Stock Futures Mostly Lower Ahead Of Jobless Claims

Loading...
Loading...
Pre-open movers
US stock futures traded mostly lower in early pre-market trade. Data on weekly jobless claims will be released at 8:30 a.m. ET. The general conditions index of the Philadelphia Fed's Survey for January and the Conference Board's index of leading indicators for January will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average dropped 31 points to 17,962.00, while the Standard & Poor's 500 index futures fell 3.70 points to 2,091.70. Futures for the Nasdaq 100 index rose 0.50 points to 4,386.50.
A Peek Into Global Markets
European markets were higher today, with the Spanish Ibex Index rising 0.31%, STOXX Europe 600 Index surging 0.06% and German DAX 30 index gaining 0.22%. French CAC 40 Index jumped 0.36% and London's FTSE 100 Index fell 0.08%. French consumer price index slipped 1% in January versus December. The eurozone's current account surplus shrank to 17.8 billion euros ($20.3 billion) in December, compared to EUR19.9 billion in November. In Asian markets, Japan's Nikkei Stock Average rose 0.36% and India's BSE Sensex climbed 0.48%. Japan's exports rose 17% y/y in January, while imports declined 9% in the month.
Broker Recommendation
Analysts at Citigroup downgraded
Huntsman CorporationHUN
from Buy to Neutral and lowered the price target to $25.00. Huntsman's shares fell 6.50% to close at $22.73 yesterday.
Breaking news
  • Shares of Priceline Group Inc. PCLN jumped over 7% in pre-market trading after the company reported stronger-than-expected results for the fourth quarter results. To read the full news, click here.
  • j2 Global, Inc. JCOM today announced that its Campaigner® Email Marketing brand has acquired the assets of EmailDirect, a California-based provider of email marketing services. To read the full news, click here.
  • Hormel Foods Corp. HRL reported better-than-expected earnings for the fiscal first quarter and lifted its earnings forecast. To read the full news, click here.
  • Genentech, a member of the Roche Group RHHBY, today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's New Drug Application (NDA) for cobimetinib in combination with Zelboraf® (vemurafenib) for the treatment of people with BRAF V600 mutation-positive advanced melanoma. To read the full news, click here.
Loading...
Loading...
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsCitigroupUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...